1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
immatics biotechnologies GmbH

immatics biotechnologies GmbH

IMTXW
immatics biotechnologies GmbHUS flagNASDAQ Capital Market
0.00
USD
+0.00
- -
72,922.00Market Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
4
18
31
35
173
54
156
48
37
Operating Margin (%)
-912.71
-178.94
-223.07
-248.24
17.33
-188.39
-24.78
-377.11
-570.3
Depreciation Expense
2
4
4
5
7
7
12
12
12
Net Income, GAAP
-31
-32
-211
-93
28
-95
15
-196
-214
Effective Tax Rate (%)
- -
- -
- -
- -
34.1
- -
28.71
- -
- -
Profit Margin (%)
-834.06
-171.13
-676.04
-268.49
16.03
-175.29
9.77
-407.01
-574.86
Working Capital
- -
55
162
57
271
293
562
461
430
LT Debt
- -
2
4
7
12
13
13
13
12
Total Equity
- -
-41
87
24
203
218
575
484
456
Return on Invested Capital (%)
- -
- -
- -
- -
15.11
- -
-6.59
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-5.55
- -
-2.73
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
14
13
12
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
122
134
137
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
458
504
485
Cash, Cash Equivalents & STI
431
469
454
Accounts Receivable, Net
3
6
4
Inventories
- -
- -
- -
Total Current Liabilities
62
43
55
Payables & Accruals
23
21
32
ST Debt
3
3
3
Deferred Revenue
26
16
13

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
165.6%
-15.79%
Free Cash Flow
- -
192.22%
5.11%
Net Income, GAAP
- -
-426.83%
-1,390.89%
Sales/Revenue/Turnover
- -
91.84%
-69.03%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
30
19
51
56
156
2025
19
5
5
20
48
2026
8
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Harpreet Singh
Full Time Employees
554
Sector
Healthcare
Industry
Biotechnology
Address
Paul-Ehrlich-Strasse 15 Tübingen United States of America 72076
IPO Date
Jul 2, 2020
CIK
0001809196
Website
immatics.com
Similar Companies
Sirnaomics Ltd. (2257.HK)
Daré Bioscience, Inc. (DARE)
Theriva Biologics, Inc. (TOVX)
Sol-Gel Technologies Ltd. (SLGL)
Nymox Pharmaceutical Corporation (NYMXF)
Xintela AB (publ) (XINT.ST)
Business
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company, develops T cell redirecting immunotherapies targeting solid tumors, including adoptive cell therapies (ACT) such as IMA203 (PRAME-targeted TCR-T) and TCR bispecifics (TCER) like IMA401 (MAGE-A4/8) and IMA402 (PRAME); its proprietary platforms enable discovery of tumor-associated peptides (TUMAPs), HLA-restricted targets, and T cell receptors for precision oncology treatments across more than 50 cancer types, with PRAME as the lead target in melanoma, lung, ovarian, breast, and endometrial cancers. Founded in 2000 and headquartered in Tuebingen, Germany, with additional sites in Munich, Germany, and Houston, Texas, USA, the company operates globally through three sites and approximately 700 employees, focusing on clinical programs in two therapeutic modalities supported by advanced bioinformatics, peptidomics, and immunomonitoring technologies. Recent developments include achievement of clinical proof-of-concept for next-generation TCER pipeline candidates IMA402 and IMA401 in November 2025, advancement of four clinical programs with active patient enrollment, and strategic collaborations such as the September 2023 research and development agreement with Moderna spanning bispecifics, cell therapy, and cancer vaccines; earlier partnerships encompass Editas Medicine (June 2022, gamma delta T cells and gene editing), Bristol Myers Squibb (2015, adoptive cell therapies), and MD Anderson Cancer Center via Immatics US, Inc.